Intercontinental Wealth Advisors LLC cut its stake in Eli Lilly And Co (NYSE:LLY) by 29.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,736 shares of the company’s stock after selling 1,528 shares during the quarter. Intercontinental Wealth Advisors LLC’s holdings in Eli Lilly And Co were worth $432,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of LLY. Ironwood Financial llc purchased a new position in Eli Lilly And Co in the 4th quarter worth approximately $30,000. Csenge Advisory Group purchased a new position in Eli Lilly And Co in the 3rd quarter worth approximately $58,000. Cornerstone Advisors Inc. lifted its stake in Eli Lilly And Co by 21.3% in the 3rd quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock worth $83,000 after purchasing an additional 136 shares in the last quarter. First Command Bank lifted its stake in Eli Lilly And Co by 31.3% in the 4th quarter. First Command Bank now owns 834 shares of the company’s stock worth $96,000 after purchasing an additional 199 shares in the last quarter. Finally, First Command Financial Services Inc. lifted its stake in Eli Lilly And Co by 31.3% in the 4th quarter. First Command Financial Services Inc. now owns 834 shares of the company’s stock worth $96,000 after purchasing an additional 199 shares in the last quarter. 76.89% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have weighed in on LLY. UBS Group reissued an “average” rating and issued a $100.00 target price (down from $107.53) on shares of Eli Lilly And Co in a research note on Friday. Cantor Fitzgerald reissued a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Barclays reissued a “buy” rating and issued a $130.00 target price on shares of Eli Lilly And Co in a research note on Sunday, January 20th. Zacks Investment Research reissued a “hold” rating and issued a $120.00 target price on shares of Eli Lilly And Co in a research note on Monday, December 31st. Finally, Argus reissued a “buy” rating on shares of Eli Lilly And Co in a research note on Thursday, December 27th. Eleven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $111.41.
LLY stock opened at $119.60 on Friday. The company has a market cap of $124.47 billion, a PE ratio of 21.55, a PEG ratio of 1.87 and a beta of 0.37. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. Eli Lilly And Co has a one year low of $73.69 and a one year high of $121.84.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The firm had revenue of $6.44 billion for the quarter, compared to analysts’ expectations of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 42.55%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.14 EPS. Analysts forecast that Eli Lilly And Co will post 5.63 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be given a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.16%. The ex-dividend date of this dividend is Thursday, February 14th. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s payout ratio is presently 40.54%.
In other news, major shareholder Lilly Endowment Inc sold 202,540 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, November 12th. The shares were sold at an average price of $113.48, for a total transaction of $22,984,239.20. Following the sale, the insider now owns 118,814,164 shares of the company’s stock, valued at approximately $13,483,031,330.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Myles O’neill sold 25,000 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, December 10th. The shares were sold at an average price of $112.92, for a total transaction of $2,823,000.00. Following the sale, the senior vice president now directly owns 26,562 shares in the company, valued at approximately $2,999,381.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,020,383 shares of company stock worth $117,579,574. Corporate insiders own 0.11% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Analyst Ratings Trading
Receive News & Ratings for Eli Lilly And Co Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly And Co and related companies with MarketBeat.com’s FREE daily email newsletter.